VEGFD and neoplasm: CPT-TMC plays a significant role in anti-lymphatic production and anti-angiogenesis, lowering the expression of VEGF-D and MMP-9, reducing LMVD, MVD and KI-67 positive cells, increasing the tumor apoptosis index, and reducing the systemic side effects caused by CPT.